-+ 0.00%
-+ 0.00%
-+ 0.00%

GENELUX- IN ADVANCED OR METASTATIC RECURRENT NSCLC, OBSERVED ANTI-TUMOR ACTIVITY IN INITIAL DOSE COHORT & OLVI-VEC GENERALLY WELL TOLERATED (PHASE 2 VIRO-25)

Reuters·01/05/2026 13:03:51

Please log in to view news